TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07513285: ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Sponsor: Acurx Pharmaceuticals Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 20 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$1,940,400

Rescue Site Savings

+$1,293,600

Unlock Full NCT07513285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07513285 Rescue Dossier →